About The Authors
Anshul Mangal is co-founder and president of Project Farma and Precision for Medicine’s Manufacturing Solutions, as well as a board member at the Alliance for Regenerative Medicines, Alliance for mRNA Medicines and IQHQ. Prior to his tenure at Project Farma, Mangal was a patent litigator at Jones Day.
As executive vice president of Project Farma, Tony Khoury spearheaded the firm’s growth in the biotech space with a focus on next-generation medicines. He has supported the industrialization of many of the first FDA-approved advanced therapies and led the creation of Project Farma’s Advanced Therapy Manufacturing Playbook.
The cell and gene therapy (CGT) space continues to make headlines and stand out as a beacon of innovation and opportunity, attracting considerable attention from investors and biotech developers. Reports consistently underscore the industry's potential, with its robust growth trajectory remaining resilient even amidst broader investment downturns. In 2023 alone, investments totaled $11.7bn.
CGTs have emerged at the forefront of biotech, offering promising solutions to address a number of previously unmet medical needs...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
